We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News COVID-19 Clinical Chemistry Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology BioResearch Industry News

BIOHIT  Healthcare OY

Immune System Altered in Chronic Fatigue Syndrome

By LabMedica International staff writers
Posted on 27 Dec 2019
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe, chronic, and debilitating disease that can cause a range of symptoms including pain, severe exhaustion, cognitive impairment, and post-exertional malaise, the worsening of symptoms after physical or mental activity.

Estimates suggest that between 836,000 and 2.5 million people in the USA may be affected by ME/CFS. It is unknown what causes the disease and there are no treatments. There is an increasing appreciation for the role of immune and metabolic dysfunction in the disease. ME/CFS has historically presented in outbreaks, often has a flu-like onset, and results in inflammatory symptoms.

Image: Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations (Photo courtesy of Cornell University)
Image: Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations (Photo courtesy of Cornell University)

A group of scientists working with Cornell University (Ithaca, NY, USA) examined biochemical reactions involved in energy production, or metabolism, in two specific types of immune cells obtained from 45 healthy controls and 53 people with ME/CFS. The investigators focused on CD4 T cells, which alert other immune cells about invading pathogens, and CD8 T cells, which attack infected cells. They analyzed glycolysis and mitochondrial respiration in resting and activated T cells, along with markers related to cellular metabolism, and plasma cytokines.

The team found that ME/CFS CD8+ T cells have reduced mitochondrial membrane potential compared to healthy controls. Both CD4+ and CD8+ T cells from ME/CFS patients had reduced glycolysis at rest, while CD8+ T cells also had reduced glycolysis following activation. ME/CFS patients had significant correlations between measures of T cell metabolism and plasma cytokine abundance that differed from healthy control subjects. They also looked at mitochondrial size and membrane potential, which can indicate the health of T cell mitochondria. CD4 cells from healthy controls and people with ME/CFS showed no significant differences in mitochondrial size or function.

Maureen Hanson, PhD, a professor of molecular biology and genetics and first study author, said, “Our work demonstrates the importance of looking at particular types of immune cells that have different jobs to do, rather than looking at them all mixed together, which can hide problems specific to particular cells. Additional studies focusing on specific cell types will be important to unravel what's gone wrong with immune defenses in ME/CFS.” The study was published on December 12, 2019 in the Journal of Clinical Investigation.

Related Links:
Cornell University


Latest Immunology News